Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.52 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185524 | 0.69 | CTNNB1 (1.00) | CTNNB1TCF7L2PKM | |
| SCHEMBL3457708 | 0.68 | CTNNB1 (0.52) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL15173803 | 0.65 | CTNNB1 (0.80) | CTNNB1TCF7L2PKM | |
| SCHEMBL16863946 | 0.64 | PKM (0.58) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL9525318 | 0.63 | CYP11B1 (0.51) | CTNNB1 | |
| Water SCHEMBL5279559 | 0.62 | PKM (0.56) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL3282304 | 0.62 | PKM (0.56) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL3279838 | 0.62 | PKM (0.56) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL3676899 | 0.62 | PKM (0.56) | CTNNB1TCF7L2PKMPOLBMAPK1 | |
| SCHEMBL13239650 | 0.61 | CTNNB1 (0.45) | CTNNB1TCF7L2PKMPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738628-B2 | Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297801-A1 | SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2016-10-13 | — | — | US | disclosed |
| US-9284299-B2 | Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150025114-A1 | SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025114-A1 | SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS | CTNNB1, CTNNBL1, CTNNA1 | CTNNB1 1/4885TCF7L2 10/4885PKM 3634/4885 |
| US-20160297801-A1 | SUBSTITUTED 1H-INDAZOL-1-OL ANALOGS AS INHIBITORS OF BETA CATENIN/TCF PROTEIN-PROTEIN INTERACTIONS | CTNNB1, CTNNBL1, CTNNA1 | CTNNB1 1/4885TCF7L2 10/4885PKM 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.